发明名称 Bupropion as a modulator of drug activity
摘要 This disclosure relates to methods administering bupropion or a prodrug thereof in conjunction with dextromethorphan to a human being. Dosage forms, drug delivery systems, and methods related to dextromethorphan or dextrorphan and bupropion or a prodrug of bupropion are also disclosed.
申请公布号 US9278095(B2) 申请公布日期 2016.03.08
申请号 US201514863284 申请日期 2015.09.23
申请人 ANTECIP BIOVENTURES II LLC 发明人 Tabuteau Herriot
分类号 A61K31/137;A61K31/485;A61K31/138 主分类号 A61K31/137
代理机构 K&L Gates LLP 代理人 K&L Gates LLP ;Cullman Louis C.;Johnson Brent A.
主权项 1. A method of increasing dextromethorphan plasma levels in a human being, comprising co-administering bupropion with about 40 mg per day to about 500 mg per day of dextromethorphan to the human being for at least eight consecutive days, wherein the human being is an extensive metabolizer of dextromethorphan in need of treatment with dextromethorphan, wherein bupropion and dextromethorphan are co-administered once or twice a day, and wherein on the eighth day that bupropion and dextromethorphan are co-administered, the co-administration results in an AUC0-12 of dextromethorphan that is at least about 20 times the AUC0-12 that would be achieved by administering the same amount of dextromethorphan without bupropion for eight consecutive days.
地址 New York NY US